Mental Health, Muscle, and the Peptide Power Struggle
Issue #8 · July 12, 2026
GLP-1 Drugs, Anxiety, and Depression: What the New Data Actually Says
A large real-world study just compared semaglutide and tirzepatide to older weight-loss drugs on mental health outcomes. The results split in an unexpected direction.
Read →
Amylin Therapies: The Next Generation of Weight-Loss Drugs Beyond GLP-1s
New clinical data from ADA 2026 and ECO 2026 shows amylin-based therapies delivering double-digit weight loss with better muscle preservation and fewer GI side effects than GLP-1s alone.
Read →
Survodutide Cuts Liver Fat by 63% and Visceral Fat by 34% — Why the Weight Loss Numbers Tell Only Half the Story
The SYNCHRONIZE-1 trial showed survodutide delivers 16.6% weight loss, but the real story is what happens to the fat you can't see — deep visceral and liver fat that drives cardiometabolic disease.
Read →
FDA Scientists vs. RFK Jr.: The Evidence Battle That Could Decide Peptide Access
FDA career scientists say there's insufficient evidence for all 7 peptides under review, directly contradicting RFK Jr.'s push to expand access.
Read →
The Weekly Dose — Issue #8
Week of July 6-12, 2026
Four stories this week, and every single one of them changes the conversation about how we think about metabolic health, mental health, and the regulatory landscape for peptides. We've got the first head-to-head comparison of GLP-1 drugs on clinical mental health outcomes, amylin therapies delivering a new tier of weight loss with cleaner side effect profiles, survodutide showing that not all fat loss is created equal, and FDA scientists drawing a line in the sand on peptide access. Let's get into it.
The biggest headline is the mental health data. We've known for a while that people on GLP-1 drugs report feeling better — less food noise, less anxiety around eating, sometimes just a general lift in mood. But this week's real-world study is the first to actually compare semaglutide and tirzepatide head-to-head against older weight-loss medications on clinical mental health outcomes. The results aren't what most people expected, and they have real implications for how clinicians think about prescribing these drugs for patients with comorbid anxiety or depression.
Meanwhile, the amylin story is accelerating fast. Three separate presentations at ADA 2026 and ECO 2026 showed amylin-based therapies hitting double-digit weight loss with better muscle preservation and fewer GI side effects than GLP-1s alone. If you're running a protocol that includes a GLP-1 agonist, the question isn't whether amylin therapies will enter the picture — it's when, and whether they'll replace or stack with what you're already doing.
GLP-1 Drugs and Mental Health: The Data Is In
This is the study everyone's been waiting for. A large real-world cohort compared semaglutide and tirzepatide against older weight-loss drugs — phentermine-topiramate, naltrexone-bupropion, and orlistat — on standardized anxiety and depression scores over 12 months. The GLP-1 group showed a statistically significant reduction in both anxiety (GAD-7 scores down 3.2 points vs. 1.1 for older drugs) and depression (PHQ-9 down 4.1 vs. 1.8). But here's the twist: tirzepatide outperformed semaglutide on the anxiety metric by a meaningful margin, which tracks with what we know about GIP receptor signaling in the amygdala.
The mechanistic story is compelling. GLP-1 receptors are expressed throughout the brain — not just in the hypothalamus for appetite regulation, but in the prefrontal cortex, hippocampus, and amygdala. Activation of these receptors modulates dopamine and serotonin signaling pathways, which explains the mood effects beyond simple weight loss. The fact that tirzepatide's dual GIP/GLP-1 mechanism produced stronger anxiolytic effects suggests GIP signaling plays a previously underappreciated role in emotional regulation. For anyone on or considering these compounds, this data shifts the risk-benefit calculation meaningfully — you're not just losing weight, you're potentially treating comorbid mental health conditions.
Amylin Therapies: The Next Weight-Loss Frontier
If GLP-1 agonists were the opening act, amylin-based therapies are shaping up to be the main event. New clinical data from ADA 2026 and ECO 2026 shows three amylin compounds — cagrilintide, eloralintide, and petrelintide — delivering weight loss in the 12-18% range with a side effect profile that's notably cleaner than GLP-1s alone. The GI symptoms that make semaglutide titration miserable for many patients? Significantly reduced with amylin therapies. And the muscle mass preservation data is striking: patients on amylin-based protocols retained 2-3x more lean mass compared to GLP-1 monotherapy at equivalent weight loss.
The mechanism is fundamentally different from GLP-1 agonists. Amylin works through the calcitonin receptor pathway, slowing gastric emptying, promoting satiety through brainstem signaling, and — critically — modulating the reward circuitry around food in a way that's more targeted than GLP-1's broad dopamine effects. Cagrisema, the cagrilintide-plus-semaglutide combination from Novo Nordisk, is furthest along in trials and showed 22.7% weight loss in the REDEFINE 1 extension data. That's not incremental improvement — it's a new tier. Every major pharma company is now building an amylin program, and for good reason.
Survodutide: The Visceral Fat Story
The SYNCHRONIZE-1 trial made headlines with 16.6% weight loss for survodutide, but the real story is buried in the body composition data. MRI imaging showed a 63% reduction in liver fat and a 34% reduction in visceral adipose tissue — the deep abdominal fat that wraps around organs and drives insulin resistance, cardiovascular disease, and NAFLD. These numbers dwarf what we see with GLP-1 monotherapy at comparable weight loss. A patient losing 16% of their body weight on semaglutide might see 20-25% visceral fat reduction; survodutide patients are seeing 34%.
Why the outsized effect on visceral fat? Survodutide is a dual GLP-1/glucagon receptor agonist. The glucagon component drives hepatic fat oxidation directly — it's literally telling the liver to burn stored fat for energy. This is a fundamentally different fat-loss mechanism than the caloric deficit driven by GLP-1 appetite suppression alone. For patients with metabolic syndrome, NAFLD, or significant visceral adiposity, this distinction matters enormously. You could lose the same number on a scale with a GLP-1, but survodutide preferentially targets the metabolically dangerous fat depot. The implications for cardiometabolic risk reduction are significant — and the 48-week extension data suggests these visceral fat improvements translate into measurable improvements in HOMA-IR, triglycerides, and liver enzyme levels.
FDA Scientists Push Back on Peptide Access Expansion
The regulatory battle over peptide access just got more complicated. FDA career scientists released briefing documents ahead of the upcoming advisory committee meeting that directly contradict the push by RFK Jr.'s office to expand access to seven peptides — BPC-157, TB-500, KPV, MOTS-c, SEMAX, Epitalon, and others. The scientists' position: there's insufficient evidence of safety and efficacy for these compounds in the indications being promoted, and the existing data doesn't meet the threshold for expanded access or compounding pharmacy availability.
This is a nuanced situation. The briefing documents aren't saying these peptides are dangerous — they're saying the evidence base doesn't meet FDA standards for the claims being made. BPC-157, for example, has extensive preclinical data showing tissue repair and anti-inflammatory effects, but the human clinical trial data is sparse and mostly from small studies with methodological limitations. TB-500 has a similar profile — promising mechanism, limited controlled human data. MOTS-c shows real metabolic effects in animal models but hasn't been tested in humans at therapeutic doses. The advisory committee will vote later this month, and the outcome will set precedent for how the FDA handles the growing peptide therapeutics space. If you're using or considering any of these compounds, this vote is worth watching closely — it could determine whether compounding pharmacies continue to have access.
Looking ahead: the survodutide data presentation at EASL next week could add more granularity to the liver fat findings, and the FDA advisory committee vote on peptides is expected by month's end. Both will shape the landscape for anyone running metabolic or longevity protocols. The amylin data is going to keep coming — expect Phase 3 readouts from eloralintide and petrelintide in Q3. And if the mental health data holds up in the planned randomized controlled trial, we could see GLP-1s prescribed specifically for anxiety and depression within 18 months. We'll be covering all of it.
Build Your Protocol With Real Data
This week covered semaglutide, tirzepatide, cagrilintide, survodutide, and seven peptides under FDA review — that's a lot of compounds with overlapping mechanisms and interaction profiles. The BioStack Generator lets you model how these compounds interact against your specific goals, dosing schedule, and risk tolerance. Plug in the GLP-1 and amylin agonists you're considering, set your objectives (fat loss, muscle preservation, mental health, cardiometabolic markers), and get a data-driven protocol that accounts for receptor cross-talk, dosing windows, and side effect management. Takes 2 minutes.
Turn This Week's Research Into Your Protocol
The BioStack Generator models how this week's compounds interact — receptor overlap, dosing timing, contraindications — and builds a personalised protocol from the evidence.
Build Your BioStackFree · No account required